Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Early SGLT-2 inhibitor therapy may be best for diabetic patients recovering from AKI-D

09 Sep 2026 bởi

For adult patients with type 2 diabetes who are recovering from dialysis-requiring acute kidney injury (AKI-D), initiating sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy within 30 days of discharge is associated with fewer adverse kidney events compared with later initiation, as shown in a retrospective study.

Early SGLT-2 inhibitor therapy may be best for diabetic patients recovering from AKI-D

09 Sep 2026

Stress hyperglycaemia after STEMI: Less common but more deadly in younger patients

08 Sep 2026 bởi

Among nondiabetic patients with first-onset ST-elevation myocardial infarction (STEMI), stress hyperglycaemia is more likely to occur in older patients but is associated with the greatest risk of mortality in younger patients, according to local research.

Stress hyperglycaemia after STEMI: Less common but more deadly in younger patients

08 Sep 2026

Sleeve gastrectomy an important option for treating teens with severe obesity, MASLD

07 Sep 2026 bởi

For adolescents with severe obesity and metabolic dysfunction–associated steatotic liver disease (MASLD), vertical sleeve gastrectomy yields greater improvements in histologic and cardiometabolic outcomes compared with comprehensive lifestyle intervention, as shown in a single-centre, nonrandomized cohort study.

Sleeve gastrectomy an important option for treating teens with severe obesity, MASLD

07 Sep 2026

Resistant starch supplementation helps improve metabolic, gut health

07 Sep 2026

A narrative review suggests the potential of resistant starch (RS) as a dietary strategy for supporting metabolic and gut health in Asia-Pacific populations undergoing rapid nutritional transition.

Resistant starch supplementation helps improve metabolic, gut health

07 Sep 2026

COPD a risk factor for osteoporosis

07 Sep 2026

Chronic obstructive pulmonary disease (COPD) appears to contribute to an increased risk of osteoporosis, as shown in a study.

COPD a risk factor for osteoporosis

07 Sep 2026

Visceral adipose tissue may predict biological ageing in middle-aged adults

04 Sep 2026

A recent study suggests dual-energy X-ray absorptiometry (DXA)-derived visceral adipose tissue (VAT) may serve as a marker of accelerated biological ageing, independent of lifestyle and adiposity measures.

Visceral adipose tissue may predict biological ageing in middle-aged adults

04 Sep 2026

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

04 Sep 2026 bởi

In patients with serious mental illness (SMI), initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with lower risks of all-cause mortality and major adverse cardiovascular events (MACEs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors, a large study has shown.

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

04 Sep 2026

Bariatric surgery outdoes GLP-1 RAs for weight loss

03 Sep 2026

Patients with obesity achieve greater weight loss with bariatric surgery than glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and tirzepatide, a study has shown.

Bariatric surgery outdoes GLP-1 RAs for weight loss

03 Sep 2026

Veligrotug improves outcomes, life quality in patients with thyroid eye disease

03 Sep 2026 bởi

A five-infusion course of veligrotug, a full antagonist monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), over 12 weeks results in improved diplopia, proptosis, and disease activity and is well tolerated in patients with active thyroid eye disease (TED), as shown in the phase III THRIVE study. Moreover, the therapeutic effect persists through week 52.

Veligrotug improves outcomes, life quality in patients with thyroid eye disease

03 Sep 2026

Mazdutide demonstrates weight-loss benefit in US cohort

03 Sep 2026

Once-weekly, subcutaneous mazdutide treatment yields meaningful reduction in bodyweight in a US cohort of adults with obesity or overweight, according to a phase II study.

Mazdutide demonstrates weight-loss benefit in US cohort

03 Sep 2026

Tin tức & Cập nhật

Xem bài viết Nội tiết

Xem

Chuyên ngành:

Early SGLT-2 inhibitor therapy may be best for diabetic patients recovering from AKI-D

Early SGLT-2 inhibitor therapy may be best for diabetic patients recovering from AKI-D

Stress hyperglycaemia after STEMI: Less common but more deadly in younger patients

Stress hyperglycaemia after STEMI: Less common but more deadly in younger patients

Sleeve gastrectomy an important option for treating teens with severe obesity, MASLD

Sleeve gastrectomy an important option for treating teens with severe obesity, MASLD

Resistant starch supplementation helps improve metabolic, gut health

Resistant starch supplementation helps improve metabolic, gut health

COPD a risk factor for osteoporosis

COPD a risk factor for osteoporosis

Visceral adipose tissue may predict biological ageing in middle-aged adults

Visceral adipose tissue may predict biological ageing in middle-aged adults

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

Bariatric surgery outdoes GLP-1 RAs for weight loss

Bariatric surgery outdoes GLP-1 RAs for weight loss

Veligrotug improves outcomes, life quality in patients with thyroid eye disease

Veligrotug improves outcomes, life quality in patients with thyroid eye disease

Mazdutide demonstrates weight-loss benefit in US cohort

Mazdutide demonstrates weight-loss benefit in US cohort